GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Altman Z-Score

Fulgent Genetics (Fulgent Genetics) Altman Z-Score

: 4.44 (As of Today)
View and export this data going back to 2016. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 4.56 is strong.

Fulgent Genetics has a Altman Z-Score of 4.44, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Fulgent Genetics's Altman Z-Score or its related term are showing as below:

FLGT' s Altman Z-Score Range Over the Past 10 Years
Min: 4.56   Med: 13.41   Max: 33.97
Current: 4.56

During the past 10 years, Fulgent Genetics's highest Altman Z-Score was 33.97. The lowest was 4.56. And the median was 13.41.


Fulgent Genetics Altman Z-Score Historical Data

The historical data trend for Fulgent Genetics's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.64 9.67 19.85 6.69 5.95

Fulgent Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.69 6.56 8.56 6.27 5.95

Competitive Comparison

For the Diagnostics & Research subindustry, Fulgent Genetics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics Altman Z-Score Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Altman Z-Score falls into.



Fulgent Genetics Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Fulgent Genetics's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.352+1.4*0.5126+3.3*-0.1409+0.6*5.8868+1.0*0.2341
=4.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $1,235.3 Mil.
Total Current Assets was $507.8 Mil.
Total Current Liabilities was $73.0 Mil.
Retained Earnings was $633.2 Mil.
Pre-Tax Income was -145.196 + 6.86 + -14.7 + -21.049 = $-174.1 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.0 Mil.
Revenue was 70.505 + 84.687 + 67.853 + 66.168 = $289.2 Mil.
Market Cap (Today) was $600.7 Mil.
Total Liabilities was $102.0 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(507.845 - 73.018)/1235.328
=0.352

X2=Retained Earnings/Total Assets
=633.175/1235.328
=0.5126

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-174.085 - 0)/1235.328
=-0.1409

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=600.704/102.042
=5.8868

X5=Revenue/Total Assets
=289.213/1235.328
=0.2341

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Fulgent Genetics has a Altman Z-Score of 4.44 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Fulgent Genetics  (NAS:FLGT) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Fulgent Genetics Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics (Fulgent Genetics) Business Description

Traded in Other Exchanges
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Executives
Jian Xie officer: Chief Operating Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao 10 percent owner, officer: Chief Scientific Officer 4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim officer: CFO and Treasurer 4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post director
Michael Nohaile director C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger director 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust 10 percent owner 4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh director 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh director, 10 percent owner, officer: President and CEO 4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc. director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay director 6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc. 10 percent owner #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663